Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

November 17, 2005 09:31 ET

Swiss Medica's O24 Fibromyalgia Receives Enthusiastic Response to Launch of National Fibromyalgia Association Awareness Campaign

TORONTO, ONTARIO--(CCNMatthews - Nov. 17, 2005) - Swiss Medica, Inc. (OTCBB:SWME) today announced that response to new marketing initiatives has been very strong with over 20,000 requests for samples of O24 Fibromyalgia being received since November 11th. Early demand for O24 Fibromyalgia at the retail level has also been very robust.

O24 Fibromyalgia was featured in a National Fibromyalgia Association news bulletin on November 10 as the first product to receive the Association's Seal of Approval. Since then, Swiss Medica has been contacted not only by thousands of people with the fibromyalgia condition, but by numerous hospitals, clinics and primary care physicians. O24 Fibromyalgia is the first clinically tested product specifically for fibromyalgia to be available in national pharmacies in the United States.

Swiss Medica's President and COO, Grant Johnson says "We have tremendous confidence in the efficacy of both O24 Pain Neutralizer and O24 Fibromyalgia, and we know from experience that if people try the products, the vast majority will experience relief from pain and become loyal users of the product. We are very proud of our strategic alignment with the National Fibromyalgia Association and know that with their support, O24 Fibromyalgia will bring relief to millions of fibromyalgia sufferers across North America."

O24 Fibromyalgia is available at leading retailers, including; Rite Aid, Longs and Albertsons. For detailed store locations, please visit

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at, and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit, for ordering details and store locators for the nearest retailer.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information